Karyopharm Therapeutics Inc (NASDAQ: KPTI) kicked off on Friday, up 8.95% from the previous trading day, before settling in for the closing price of $6.37. Over the past 52 weeks, KPTI has traded in a range of $3.51-$12.45.
A company in the Healthcare sector has jumped its sales by 27.91% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 12.70%. With a float of $15.85 million, this company’s outstanding shares have now reached $17.05 million.
Karyopharm Therapeutics Inc (KPTI) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Karyopharm Therapeutics Inc is 7.05%, while institutional ownership is 40.55%. The most recent insider transaction that took place on Oct 01 ’25, was worth 2,279. In this transaction Chief Accounting Officer of this company sold 362 shares at a rate of $6.30, taking the stock ownership to the 10,046 shares. Before that another transaction happened on Sep 15 ’25, when Company’s President and CEO sold 1,257 for $6.43, making the entire transaction worth $8,083. This insider now owns 84,046 shares in total.
Karyopharm Therapeutics Inc (KPTI) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -3.6 earnings per share (EPS), higher than consensus estimate (set at -4.03) by 0.43. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.56 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 49.66% during the next five years compared to 27.91% growth over the previous five years of trading.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Trading Performance Indicators
Take a look at Karyopharm Therapeutics Inc’s (KPTI) current performance indicators. Last quarter, stock had a quick ratio of 0.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -14.58, a number that is poised to hit -2.08 in the next quarter and is forecasted to reach -5.90 in one year’s time.
Technical Analysis of Karyopharm Therapeutics Inc (KPTI)
Let’s dig in a bit further. During the last 5-days, its volume was 0.24 million. That was better than the volume of 0.14 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 40.69%.
During the past 100 days, Karyopharm Therapeutics Inc’s (KPTI) raw stochastic average was set at 73.11%, which indicates a significant decrease from 75.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.53 in the past 14 days, which was lower than the 0.54 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.95, while its 200-day Moving Average is $5.46. However, in the short run, Karyopharm Therapeutics Inc’s stock first resistance to watch stands at $7.21. Second resistance stands at $7.47. The third major resistance level sits at $7.86. If the price goes on to break the first support level at $6.56, it is likely to go to the next support level at $6.17. The third support level lies at $5.91 if the price breaches the second support level.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Key Stats
The company with the Market Capitalisation of 118.33 million has total of 17,051K Shares Outstanding. Its annual sales at the moment are 145,240 K in contrast with the sum of -76,420 K annual income. Company’s last quarter sales were recorded 44,040 K and last quarter income was -33,130 K.
